pharmaphorum

JANUARY 18, 2023

The DNA of these so-called ‘genetic superheroes’ may contain clues about how to treat severe disease. Fast forward to today and, while many large-scale genomics studies still lack the infrastructure and consent policies to enable recontact, this is starting to change. Giving participants something in return.

Genetic Disease 97

Genetic Disease Genetics Research Genome 97

XTalks

APRIL 24, 2023

Rare disease clinical trials are complex due to the additional scientific, medical, operational and regulatory requirements of newly emerging advanced therapies, such as gene therapy,” says Dr. Terence Eagleton, MB BS, Senior Medical Director at the global clinical research organization (CRO) Medpace. Reference: Chung DC, et al.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

XTalks

APRIL 15, 2021

Late-stage clinical trial failures are largely to blame for the lack of effective treatment options for patients with HFpEF, and poor five-year survival rates make this an area of great unmet need. New advances in heart failure genomics are helping to address this challenge. Heart failure affects about 6.2

Development 98

Development Drugs Genome Genomics 98

Delveinsight

DECEMBER 13, 2020

Even though clinical trial results were promising, adverse events and serious complications were observed. Hepatitis C treatment options, without a doubt, have improved significantly, including pan-genotypic medications that are used to treat all genotypes and subtypes. Both drugs resulted in inhibition of HCV replication.

Genotype 52

Genotype FDA Approval DNA Drugs 52

XTalks

FEBRUARY 4, 2021

The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Genuity Science focuses on population genomics as a tool to derive novel biological insights through partnerships with industry-leading pharmaceutical and biotech companies.

Research 98

Research Biobanking Drugs Genome 98

The Pharma Data

SEPTEMBER 2, 2021

Multiple trials reinforce the efficacy of Imfinzi combinations, including with novel immunotherapies, for lung cancer patients across settings. DESTINY-Breast03 is the first global Phase III trial of Enhertu against an active control.

Trials 52

Trials Medicine Antibody Clinical Trials 52